Supplementary Figures from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Supplementary Figure 1 ARID1A mutations in the panel of OCCC tumour cell line models with corresponding protein expression. Supplementary Figure 2 Un-cropped western blots from main and supplementary figures. Supplementary Figure 3 ARID1A selective effects from the high throughput drug screen. Supplementary Figure 4 Inhibitors of the PI3K/mTOR signalling pathway in the panel of OCCC cell lines and ARID1A selectivity. Supplementary Figure 5 Dasatinib is a synthetic lethal drug in ARID1A mutant OCCC tumour cell line models - see also Figure 2. Supplementary Figure 6 Dasatinib sensitivity in ARID1A mutant isogenic HCT116 colorectal tumour cell line model. Supplementary Figure 7 Dasatinib siRNA screen results. Supplementary Figure 8 Apoptosis assay in four OCCC cell line models, see also Figure 4. Supplementary Figure 9 Dasatinib sensitivity in ARID1A mutant OCCC is dependent upon G1/S checkpoint effectors, see also Figure 5. Supplementary Figure 10 Determining the optimal method of dasatinib delivery in vivo.